IBD Rating Upgrades: TwistBioscienceCorp Flashes Improved Price Strength

The Relative Strength (RS) Rating for TwistBioscienceCorp (TWST) headed into a new percentile Monday, as it got a lift from 67 to 77.


When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

IBD’s unique rating identifies market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock’s price behavior over the trailing 52 weeks compares to all the other stocks in our database.

History reveals that the best stocks often have an 80 or higher RS Rating in the early stages of their moves. See if TwistBioscienceCorp can continue to show renewed price strength and hit that benchmark.

See How IBD Helps You Make More Money In Stocks

TwistBioscienceCorp is now considered extended and out of buy range after clearing a 36.01 buy point in a first-stage consolidation. See if the stock forms a new chart pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.

While sales growth fell last quarter from 64% to 62%, earnings-per-share grew 8%, up from 0% in the previous report. The next quarterly results are expected on or around Aug. 6.

TwistBioscienceCorp earns the No. 73 rank among its peers in the Medical-Biomed/Biotech industry group. Maravai Lifesciences (MRVI) and Avid Bioservices (CDMO) are also among the group’s highest-rated stocks.


Biotech And Pharmaceutical Industry And Stock News

Which Stocks Are Showing Rising Relative Strength?

Why Should You Use IBD’s Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

Find Top Stocks Near A Buy Point With IBD Leaderboard

Most Related Links :
reporterwings Governmental News Finance News

Source link

Back to top button